A5057100726- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Transplantation: Methods and Outcomes
- Chronic Myeloid Leukemia Treatments
- Galectins and Cancer Biology
- Cardiac, Anesthesia and Surgical Outcomes
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Lung Cancer Treatments and Mutations
- Acute Kidney Injury Research
- Obstructive Sleep Apnea Research
- Renal Transplantation Outcomes and Treatments
- Acute Lymphoblastic Leukemia research
- Renal Diseases and Glomerulopathies
- Endoplasmic Reticulum Stress and Disease
- Cytomegalovirus and herpesvirus research
- Monoclonal and Polyclonal Antibodies Research
- Sleep and Wakefulness Research
- Frailty in Older Adults
- RNA regulation and disease
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Occupational and environmental lung diseases
- Mycobacterium research and diagnosis
- Organ Transplantation Techniques and Outcomes
Mayo Clinic in Arizona
2022-2024
Mayo Clinic
2022-2024
University of Toronto
2019-2024
The University of Texas MD Anderson Cancer Center
2024
WinnMed
2022-2023
University Health Network
2022
Toronto General Hospital
2022
University of Birmingham
2020
University of Ottawa
2015-2019
Brigham and Women's Hospital
2019
Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, that predominately affects the elderly. We report outcomes of young WM patients, evaluated over five decades, compared to their older counterparts, matched for time diagnosis. Between January 1, 1960 and October 31, 2013, 140 (11.8%) patients were ≤50 years age at diagnosis in our database, estimated 10-year overall survival (OS) was 74%, with death attributable higher proportion (≥65 years) counterparts (91% vs. 58%, p =...
Recent findings suggest that dopamine oxidation contributes to the development of Parkinson's disease (PD); however, mechanistic details remain elusive. Here, we compare 6-hydroxydopamine (6-OHDA), a product commonly induces dopaminergic neurodegeneration in laboratory animals, with synthetic alkyne-functionalized 6-OHDA variant. This molecule provides insights into reactivity quinone and neuromelanin formation. Employing Huisgen cycloaddition chemistry (or "click chemistry") fluorescence...
Background Approximately 50% of patients with interstitial lung disease (ILD) experience frailty, which remains unexplored in acute exacerbations ILD (AE-ILD). A better understanding may help prognostication and resource planning. We evaluated the association frailty clinical characteristics, physical function, hospital outcomes, post-AE-ILD recovery. Methods Retrospective cohort study AE-ILD (01/2015–10/2019) (proportion ≥0.25) on a 30-item cumulative-deficits index. Frail non-frail were...
Hodgkin lymphoma is a B-cell malignancy with approximately 85-95% complete remission rate following frontline therapy; however, relapsed/refractory disease occurs in roughly 10-30% of patients after treatment. Salvage therapy conventionally relies upon cytotoxic chemotherapy followed by high-dose and autologous stem cell transplantation. A considerable number experience relapse transplantation, further salvage management has included the use allogeneic transplantation radiotherapy. In past...
Background. Malnutrition in lung transplant (LTx) candidates is an important risk factor for adverse outcomes. We sought to evaluate the Nutritional Risk Index (NRI) LTx candidates, a validated measure of malnutrition chronic disease. aimed characterize using NRI, change body weight between nutritional groups, and assess association with pretransplant posttransplant Methods. Retrospective, single-center cohort study (2014–2015) evaluated by dietitian before listing. parameters,...
Multiple clinical trials have assessed de-escalation strategies from combined modality therapy (CMT) to chemotherapy-alone for the treatment of early-stage classical Hodgkin lymphoma (cHL), confirming similar outcomes. The application these data real-world is limited, however. We conducted a retrospective, multicenter cohort study comparing CMT vs in patients with cHL (stage IA-IIB) treated between January 2010 and December 2020. Positron emission tomography (PET) scans after chemotherapy...
Lung transplant (LTx) candidates experience significant respiratory symptoms often necessitating palliative care (PC) support. We aimed to describe experienced by interstitial lung disease (ILD) and chronic obstructive pulmonary (COPD) LTx referred for PC using the Edmonton Symptom Assessment System (ESAS) assess change in ESAS relation pre-LTx exercise capacity, oxygen requirements, exacerbations. Understanding symptom trajectory of these two patient groups will help inform...
Waldenström macroglobulinemia (WM) is a rare, non-Hodgkin lymphoma that remains incurable. Rituximab, an anti-CD20 monoclonal antibody has been the cornerstone of treatment against WM, and its combination with alkylator, bendamustine, achieves durable remission in treatment-naive patients symptomatic WM. However, novel “druggable” targets have identified within clonal lymphoplasmacytic cells WM resulted rapid development targeted therapies both frontline relapsed refractory (R/R) settings....
Click to increase image sizeClick decrease size AcknowledgementsNone note.Author contributionsK.L.C and S.S.K designed the study, analyzed, interpreted data, wrote manuscript. R.B, M.A.H., J.P, N.N.B., P.B.J., A.K., U.D., Y.W., M.W.R., J.C.V.B., S.M.A., Y.L. data assisted in writing All authors approved of final manuscript.Disclosure statementS.S.K. is inventor on patents CAR-T cell field that are licensed Novartis (through an agreement between Mayo Clinic, University Pennsylvania,...
Considerable healthcare resource utilization and financial burden have been associated with the treatment of WM; however, impact health insurance status on outcomes has not previously reported. We conducted a National Cancer Database analysis newly diagnosed cases active WM between 2004 2017 to evaluate outcomes. For patients <65 years old (n = 1249, male sex: 62.4%, median age: 58 years), significant insurance-based survival differences were observed multivariable analysis; who uninsured [n...